Senores Pharmaceuticals Reports 72% Y-o-Y Increase in Q1 FY26 Profit After Tax

Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, has announced its un-audited Financial Result for the first Quarter of FY26 ended 30th June 2025. The company reported a 72% Year-over-Year (Y-o-Y) increase in Profit After Tax (PAT) for Q1 FY26. The total income stood at Rs. 138 Crs, with EBITDA at Rs. 34 Crs. The Regulated Markets revenue grew by 69% Y-o-Y, while the Emerging Markets revenue increased by 32% Y-o-Y. The company launched 2 own ANDA products in the Regulated Markets during the quarter and received ANDA approval for 4 products. The CDMO/CMO segment is also scaling up as planned. The company reported a positive Operating Cash Flow of Rs 11 crores for Q1FY26.